Pasar al contenido principal

VALIDACION CLINICA DE UN SISTEMA PARA DETECTAR TRANSLOCACIONES DE ALK EN VESICULAS EXTRACELULARES EN PLASMA III

DTS21/00124

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Desarrollo Tecnológico en Salud
Año convocatoria 2021
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION INVESTIGACION BIOMEDICA HOSPITAL PUERTA DE HIERRO
Centro realización INSTITUTO DE INVESTIGACION SANITARIA DEL HOSPITAL UNIV. PUERTA DE HIERRO MAJADAHONDA (IDIPHIM)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Optimized size exclusion chromatography demonstrates that extracellular vesicles are the key RNA carriers of ALK translocations in non-small cell lung cancer cell line secretome and patient plasma

  • Benayas, Beatriz
  • Sánchez-Herrero, Estela
  • Robado de Lope, Lucía
  • Morales, Joaquín
  • López-Martín, Soraya
  • Provencio, Mariano
  • Valés-Gómez, Mar
  • Romero, Atocha
  • Yáñez-Mó, María
Aim: Identification of ALK fusions in non-small cell lung cancer (NSCLC) is key to determining eligibility for treatment with ALK inhibitors that markedly improve patients' quality of life and survival outcomes. Circulating RNA, associated with various carriers including extracellular vesicles (EVs), lipoproteins (LPPs), or protein complexes, presents a viable target for the identification of ALK fusions by liquid biopsy. Our aim was to characterize the specific carrier of ALK fusion RNA, a crucial step in the development of diagnostic methods for clinical use. Methods: We employed optimized size-exclusion chromatography (SEC) to separate EVs, LPPs, and protein-enriched fractions from ALK-positive NSCLC cell lines and from pools of plasma obtained from NSCLC patients with ALK translocations. We optimized RNA fusion transcript detection using digital PCR (dPCR). Results: Protein analyses confirmed the successful resolution of EVs, LPPs, and protein fractions by optimized SEC. Our dPCR results indicated that ALK fusions were more prevalent in tetraspanin-enriched SEC fractions from NSCLC cell lines, suggesting that EVs serve as the primary carrier for ALK fusion RNA. After optimization for larger volumes of samples of the RNA isolation protocol, we could also demonstrate that ALK fusion transcripts were found exclusively in EVs from patient plasma. Of note, the circulating number of copies of the transcript was below 5 copies/mL. Discussion: Our findings underscore the potential of EV-associated RNA as a promising source for detecting ALK fusion variants in plasma samples from NSCLC patients, offering a non-invasive diagnostic approach with significant clinical implications., This work was supported by grants PID2020- 119627GB-I00 (MY-M) PID2021-123795OB-I00 (MVG) from the Spanish Ministry of Science and Innovation [Ministerio de Ciencia e Innovación (MCIN)/Agencia Estatal de Investigación (AEI) (MCIN/AEI/ 10.13039/501100011033) and the European Regional Development Fund (ERDF)-A way of making Europe] and by Instituto de Salud Carlos III through the projects (PI21/01500, DTS21/00124, and DTS21/00134) (co-funded by the European Regional Development Fund/European Social Fund). Benayas B was supported by a graduate industrial contract (IND2019_BMD-17100) and Morales J by the (PEJ-2023-AI_SAL-GL-26725) contract, both from Comunidad Autónoma de Madrid. Robado de Lope L was supported by a Juan de la Cierva fellowship (JDC2022-049091-I)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Detecting ALK, ROS1, and RET fusions and the METΔex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques

  • Giménez-Capitán, Ana|||0000-0003-2575-1225
  • Sánchez-Herrero, Estela
  • Robado de Lope, Lucía
  • Aguilar-Hernández, Andrés
  • Sullivan, Ivana|||0000-0002-0434-3436
  • Calvo, Virginia|||0000-0002-3503-4847
  • Moya-Horno, Irene
  • Viteri, Santiago|||0000-0002-7572-1123
  • Cabrera-Galvez, Carlos
  • Aguado, Cristina
  • Armiger, Noelia
  • Valarezo, Joselyn
  • Mayo-de-las-Casas, Clara
  • Reguart, Noemi|||0000-0001-8190-499X
  • Rosell, Rafael|||0000-0003-0817-3400
  • Provencio Pulla, Mariano|||0000-0001-6315-7919
  • Romero, Atocha|||0000-0002-1634-7397
  • Molina Vila, Miguel Ángel|||0000-0001-8866-9881
ALK, ROS1, and RET fusions and MET∆ex14 variant associate with response to targeted therapies in non-small-cell lung cancer (NSCLC). Technologies for fusion testing in tissue must be adapted to liquid biopsies, which are often the only material available. In this study, circulating-free RNA (cfRNA) and extracellular vesicle RNA (EV-RNA) were purified from liquid biopsies. Fusion and MET∆ex14 transcripts were analyzed by nCounter (Nanostring) and digital PCR (dPCR) using the QuantStudio System (Applied Biosystems). We found that nCounter detected ALK, ROS1, RET, or MET∆ex14 aberrant transcripts in 28/40 cfRNA samples from positive patients and 0/16 of control individuals (70% sensitivity). Regarding dPCR, aberrant transcripts were detected in the cfRNA of 25/40 positive patients. Concordance between the two techniques was 58%. Inferior results were obtained when analyzing EV-RNA, where nCounter often failed due to a low amount of input RNA. Finally, results of dPCR testing in serial liquid biopsies of five patients correlated with response to targeted therapy. We conclude that nCounter can be used for multiplex detection of fusion and MET∆ex14 transcripts in liquid biopsies, showing a performance comparable with next-generation sequencing platforms. dPCR could be employed for disease follow-up in patients with a known alteration. cfRNA should be preferred over EV-RNA for these analyses.